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Abstract
The early diagnosis of pancreatic cancer, as well as distinguishing between chronic pancreatitis and
malignant pancreatic disease, remains still a clinical problem. Presently, there is no specific tumor
marker for diagnosing pancreatic cancer. Mucin-associated marker like CA 19-9 are the most
widely available pancreatic cancer tumor marker, but its value as a screening marker is limited by
its reduced specificity.
Mucins (MUCs) are heavily glycosylated, high molecular weight glycoproteins with an aberrant
expression profile in various malignancies.
This review considers briefly the potential use of the mucin expression pattern in diagnosis of
pancreatic neoplasm. The overview will point out the present knowledge about changes in the
mucin gene expression in pancreatic intraepithelial neoplasia (PanINs) as precursor lesions and in
pancreatic adenocarcinoma, compared to normal pancreas and chronic pancreatitis and the
potential role for differentiating chronic pancreatitis from pancreatic cancer.
Furthermore, the potential use of MUCs in the diagnosis and differentiation of intraductal papillary-
mucinous neoplasm's (IPMNs) will be discussed.
Review
Pancreatic adenocarcinoma is a neoplasm with a relatively
high incidence and an extraordinarily poor prognosis [1].
In Western countries, it is the fifth leading cause of cancer
deaths and has the lowest 5-year survival rate of any can-
cer [2]. Despite advances in diagnostic imaging, methods
like endoscopic ultrasonography, dualphase spiral com-
puter tomography, magnetic resonance imaging, and en-
doscopic retrograde cholangiopancreatography, early
diagnosis and differentiation between malignant pancre-
atic tumors and chronic pancreatitis is still a diagnostic
problem for clinicians [3].
The most commonly used clinical tests for tumor markers
are serum-based immunoassays for blood group-related
antigens and glycoproteins like CA 19-9, DUPAN2, CA
50, CA 125, and more recently CA 242. In pancreatic can-
cer, the sensitivity of the CA19-9 serum assay has been
shown to range from 69% to 93%, and the specificity var-
ied between 46% and 98% [4,5]. Unfortunately, elevated
levels of the CA 19-9 antigen were found in chronic pan-
creatitis and other cancer conditions [5,6].
Antigens such as CA 19-9, CA 50, CA 125, and CA 242
contain oligosaccharide structures present on heavily gly-
cosylated high molecular weight mucins [7]. These mole-
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cules are widely synthesized and expressed by epithelial
cells of the gastrointestinal, respiratory, and genito-uri-
nary tracts [8]. Mucins are synthesized either as mem-
brane-bound or as secreted glycoproteins. The structure of
epithelial mucins displays a protein backbone bearing nu-
merous carbohydrate side chains. The structure of the
apomucin backbone typically reveals the presence of Ser/
Thr/Pro-rich regions containing tandemly repeated
stretches of amino acids that constitute potential O-glyco-
sylation sites [9].
So far 14 mucin genes have been described, eight are now
well-characterized; these include MUC1-4,  MUC5B,
MUC5AC, MUC6 and MUC7 [8–10]. Two other mucins,
MUC8 and MUC9 have also been described but their char-
acterization is yet to be completed [11,12]. Recently, par-
tial cDNA sequences for MUC11 and MUC12 have been
published [13]. Currently, MUC13 was identified as a cell
surface mucin expressed by epithelial cells as well as he-
matopoietic cells [14]. MUC16 is the most recent member
to the MUC protein family. It was characterized from a
partial cDNA sequence encoding a mucin that has long
been known as the ovarian cancer marker CA125 [15,16].
Under normal circumstances, mucins are known to play a
protective role for epithelial tissues. In addition, their in-
volvement in the renewal and differentiation of the epi-
thelium, modulation of cell adhesion, as well as cell
signaling has also been proposed.
Alterations in the expression and in the structure of mu-
cins have been reported in both pre-neoplastic and neo-
plastic lesions [17,18]. However, there is a growing
incidence that mucins and their associated blood group
antigens may assist in the diagnosis of malignancies. In
that regard, MUCs may represent potential diagnostic
markers for early detection of pancreatic cancer and spe-
cific discrimination between pancreatic cancer and benign
pancreatic diseases.
MUCs in normal pancreas
Various studies have analyzed the expression profiles of
mucins in human pancreas under normal and pathologi-
cal conditions using various methods with differences in
their specificity and sensitivity including immunochemis-
try, in situ hybridization, RT-PCR and Northern blot. In
general, immunochemical data obtained by using anti-
bodies raised against the tandem repeat peptide should be
analyzed with caution because the staining intensity may
be caused by a changed mucin protein expression or by an
altered glycosilation. Therefore, immunochemistry
should be correlated with another method such as in situ
hybridization. Despite the different analyzing methods
the studies differ also in the inclusion or exclusion of
MUCs.
Reports have shown the expression of MUC1 and MUC6
in normal adult pancreas tissue [19–22]. Our recently
published RT-PCR and Northern blot data support these
data and demonstrate the absence of MUC2,  MUC3A,
MUC4, and MUC7  mRNA in normal pancreatic tissue
[19]. There are contrary data about the detection of
MUC5AC and MUC5B in normal pancreas [19,22,23].
MUC5B mRNA was detected in normal pancreas tissue as
well as in normal duct cells by in situ hybridization
[19,23,24]. Recently MUC5AC mRNA was found by the
highly sensitive RT-PCR and slot blot analyses in normal
pancreas tissue [19]. Studies using Northern blot analyses,
in situ hybridization and immunohistochemistry did not
show any MUC5AC in pancreatic duct cells [22,23].
However, normal pancreatic duct cells seem to express
predominantly MUC1 and MUC6 [7,37]. In general,
MUC1 is a member of the membrane-bound mucins,
whereas MUC6 is a secreted gel-forming mucin. MUC6 as
a member of the group of mucins including MUC2,
MUC5AC and MUC5B is located within the 11p15 chro-
mosomal locus. In addition, no MUC2, MUC4, or MUC7
expression was detected in normal pancreas.
MUC molecules in PanINs and ductal adenocarcinoma
Approximately 80–90% of tumors of the exocrine pancre-
as are adenocarcinomas with ductal cell origin. However,
a relationship between hyperplastic and dysplastic epithe-
lial lesions of the pancreatic ducts and invasive ductal car-
cinoma are described for a long time. Therefore, similar to
the adenoma-carcinoma sequence model for colon cancer
development, the present ductal pancreatic cancer model
is based on the concept of intraepithelial neoplasia and
describes a series of lesions termed PanIN (pancreatic in-
traepithelial neoplasia). Each grade of PanINs (PanIN-1A,
PanIN-1B, PanIN-2 and PanIN-3) based on morphologi-
cal criteria, cytological and architectural atypia [25]. This
classification scheme with increasing neoplastic potential
parallels with the stepwise prevalence of genetic altera-
tions. Studies have shown, that characteristic genetic
changes of the invasive ductal carcinoma such like p53
mutations and the loss DPC4/SMAD4 are a late event in
the PanIN development whereas the overexpression of
p21WAF1/CIP1 is an early event in the precursor lesions
[26].
According to the studies about the occurrence of muta-
tions and other genetic alterations in PanINs and pancre-
atic ductal adenocarcinoma (DAC) there is an increasing
knowledge about the expression of MUC mucins in DAC
and the precursor lesions.
Studies have shown, that DACs and tumor cell lines com-
monly overexpress MUC1 mucin [7,19,22,27]. This mu-
cin was detected only at low levels in the most chronicMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/9
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pancreatitis and normal pancreas tissues on RNA level
[19]. Recently, overexpression of MUC1 was observed in
all stages of PanINs indicating the early occurrence of
MUC1 in the development of DACs. Furthermore, pub-
lished data indicate qualitative differences between the ex-
pression patterns showing cytoplasmatic and membrane-
bound MUC1 in malignant pancreatic cancer cells [27]. In
contrast, no cytoplasmatic staining was seen in normal tis-
sue and chronic pancreatitis [27]. Pancreatic cancer cells
are characterized by an aberrant glycosilation pattern. In
this context, sialynated MUC1 was detected in DACs
whereas it was not observed in specimens from normal
pancreas, chronic pancreatitis or ductal hyperplasia [28].
The de novo expression of MUC4 in pancreatic adenocarci-
noma and cell lines has been reported, a mucin that is
usually undetectable in normal pancreas [19,20,23,24].
Recently, we demonstrated the aberrant MUC4 mRNA ex-
pression in 75% (12/16) of the pancreatic adenocarcino-
ma and 73% (11/15) established pancreatic cancer cell
lines [19]. There was no expression of MUC4 in normal
pancreas (0/7) or in chronic pancreatitis tissues (0/10)
[19]. This study introduces MUC4 as a tumor-associated
mucin that was specific form pancreatic adenocarcinoma
and that may serve as diagnostic marker to discriminate
pancreatic adenocarcinoma from chronic pancreatitis. Re-
cent published data about the MUC4 expression on pro-
tein level including samples from all PanIN grades and 25
invasive pancreatic adenocarcinoma detected MUC4 in all
PanIN grades but with increasing percentage in PanIN-3
lesions (11/13) compared to PanIN-1 (5/30), PanIN-2
(10/28) [29]. 89% of the investigated DACs were MUC4
postive [29]. Interestingly, few nonneoplastic lesions in-
cluding reactive ducts in chronic pancreatitis were immu-
noreactive. More comprehensive studies including the
correlation of immunohistochemistry with other meth-
ods like in situ hybridization may be necessary to confirm
these data.
Beside the expression of the full length precursor of
MUC4 (sv0-MUC4) with the soluble glycoprotein subunit
MUC4α and the transmembrane growth factor-like subu-
nit MUC4β pancreatic cancer cells express MUC4 various
splice variants [30,31].
Another study corroborates the potential role of MUC4 as
a diagnostic marker for pancreatic cancer. This pilot study
demonstrate the presence of MUC4 mRNA in peripheral
blood mononuclear cells of pancreatic cancer patients
whereas it was undetectable in PBMCs of healthy volun-
teers or patients with pancreatitis or patients affected by
other cancer types [32].
At this time, the biological function of human MUC4 in
epithelial cells and malignant cells is poorly understood
and remains under evaluation. In addition to its involve-
ment in the covering of luminal epithelia, recent studies
suggest that the overexpression of the MUC4 rat homo-
logue sialomucin complex (SMC) disrupts integrin-medi-
ated cell-matrix and cell-cell interaction and inhibits
immune recognition [33]. The putative function of MUC4
as adhesion molecule was supported by the description of
the new extracellular domain AMOP (adhesion-associat-
ed domain in MUC4 and other proteins) [34].
In a recent study, overexpression of MUC6 and the de
novo expression of gastric secretory mucin MUC5AC in all
stages of PanINs and in invasive DACs was described on
RNA and protein level [22]. It suggests the early involve-
ment of MUC6 and MUC5AC in the carcinogenesis of the
DUCs. Additionally, a correlation between the MUC6 de-
tection and the degree of differentiation of the infiltrating
pancreatic adenocarcinoma detecting MUC6 predomi-
nantly in well-differentiated and less in moderately differ-
entiated neoplasms was seen. Poorly differentiated
tumors were only in 9% MUC6 positive.
In contrast to former published data indicating an aber-
rant expression of MUC3 in pancreatic cancer probes a re-
cent study using RT-PCR and primer located in the non-
repetitive MUC3A specific sequence did not reveal any
MUC3 mRNA detection in normal pancreas, chronic pan-
creatitis nor pancreatic cancer tissue samples [19,24,35].
In contrast to the new study, former studies are based on
data using repetitive-sequences. The authors suggest that
the detection of MUC3A in previous studies is the result of
cross-hybridization with the recently discovered mucins
MUC11 and /or MUC12. MUC3A, MUC12 and the partic-
ular characterized MUC11 share sequence homologies. In
support of this hypothesis MUC11 and MUC12 mRNA
was found in all investigated pancreatic tissues [19].
Mucin gene expression in intraductal papillary-mucinous 
pancreatic neoplasia and related lesions
Intraductal papillary-mucinous pancreatic neoplasia (IP-
MN) also called Intraductal papillary-mucinous pancreat-
ic tumors (IPMT) are a distinct and rare entity of
pancreatic disease characterized by a proliferation of the
epithelium lining the pancreatic ducts [36]. In contrast to
the DACs IPMN have in general a better clinical prognosis
and can be cured by surgery. Therefore, the correct diagno-
sis has an important clinical impact. Their relationship to
the PanINs and DACs is still not well defined. IPMN may
progress from adenomas stepwise to intraductal carcino-
mas and then to invasive carcinoma. However, molecular
analyses demonstrate genetic alterations like the loss of
DPC4 in distinct invasive forms of IPMNs, PanIN-3 as
well as in DACs. Various studies demonstrate a dysregula-
tion of mucins in IPMNs, which might contribute to the
neoplastic progression. Studies revealed that IPMNs inMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/9
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general express MUC2, MUC5AC and mostly MUC4
whereas MUC1 is absent [36–39]. This is in contrast to the
invasive DACs, which are characterized by an overexpres-
sion of MUC1 and the absence of MUC2. However, recent
data suggest a more heterogeneous profile of IPMNs with
different mucin patterns and different clinical prognosis.
It seems to be that there are at least three groups of IPMNs
differing in their mucin expression. The largest group is
MUC2 positive and MUC1 negative. A second group of IP-
MNs is MUC1 positive and MUC2 negative with an in-
creased tendency for invasion and seems to be related to
DAC. The third group with an oncocytic histology is char-
acterized by a focal MUC1 and MUC2 expression [36]. IP-
MNs with a high expression of MUC2 and MUC5AC have
a lower invasion and metastasising potential in compari-
son to DACs and therefore a better clinical outcome [36–
39]. In contrast, other data demonstrate that within the
IPMNs MUC2 positive tumors have a higher incidence for
malignant transformation and invasive behaviour than
MUC2 negative tumors [38]. However, the authors point
out that both groups of IPMNs have still a significant bet-
ter clinical outcome than DACs.
Other rare neoplasms of the pancreas are the mucinous
cystic neoplasms (MCNs). MNCs are unilocular or, more
commonly, multilocular cysts lined by tall mucin produc-
ing cells. They affect almost woman and occur predomi-
nantly in the tail of the pancreas [40]. MCNs may be
misdiagnosed as IPMNs or cystic forms of DACs. But in
contrast to the most DACs non-invasive MCNs can be
cured by surgery. A recent study has shown that non-inva-
sive MCNs can be distinguished from IPMNs and DACs
by the mucin profile that is characterized by expression of
MUC5AC, whereas MUC2 expression is restricted to
globlet cells [40]. Similar to DACs invasive forms of
MCNs are MUC1 positive. In this regard, MUC1 expres-
sion in pancreatic lesions correlates with a more aggres-
sive biological behaviour.
Conclusion
In summary, the early diagnosis of pancreatic cancer, as
well as distinguishing between benign (chronic pancreati-
tis) and malignant pancreatic disease, remains difficult
and may require multiple approaches including the imag-
ing studies and tissue sampling. The analysis of the mucin
expression pattern might be a promising tool to improve
the correct diagnosis of pancreatic cancer. Several studies
have shown that the mucin profile correlates with the
growth behaviour and the prognosis of DACs, IPMNs and
MCNs. In general, MUC1 expression is associated with a
more aggressive biological behaviour. Therefore, mucins
might be an important prognostic marker.
Despite, increasing knowledge about the mucin expres-
sion profile in normal pancreas, PanINs and DACs,
chronic pancreatitis tissues were included only in few
studies. However, the discrimination between pancreatic
adenocarcinoma and chronic pancreatitis is still a pressing
clinical problem. In this moment, MUC4 as a pancreas tu-
mor-associated mucin seems to be a potential discrimina-
tion marker. But it has to be mentioned that despite the
high frequency of MUC4 occurrence in pancreatic cancer
a fraction is MUC4 negative.
The combined implementation of conventional imaging
techniques and molecular diagnostic approaches includ-
ing investigation of the mucin expression pattern may
provide improved sensitivity and specificity of diagnosis
of pancreatic cancer. Overall, further studies are necessary
to confirm the clinical value of mucins in diagnosis of
pancreatic diseases.
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